Genelux (GNLX) Revenue (2022 - 2024)
Genelux (GNLX) posted quarterly Revenue of $8000.0 for Q1 2024, down 95.29% year-over-year from $170000.0 in Q2 2023, and down 95.29% quarter-over-quarter from $170000.0 in Q1 2023.
Genelux (GNLX) Revenue (2022 - 2024) Analysis & Trends
Genelux's Revenue history runs 3 years deep, the most recent figure standing at $8000.0 for Q1 2024.
- In Q1 2024, Revenue fell 95.29% year-over-year to $8000.0; the TTM figure through Dec 2024 stood at $8000.0 (down 95.29% YoY), while the FY2025 annual figure was $8000.0, changed 0.0% from the prior year.
- Revenue for Q1 2024 stood at $8000.0, down from $170000.0 in the prior quarter.
- The five-year high for Revenue was $11.0 million in Q3 2022, with the low at -$10.8 million in Q4 2022.
- The 3-year median for Revenue is $89000.0 (2023), against an average of $87000.0.
- Peak annual rise in Revenue reached 95.29% in 2024, while the deepest fall reached 95.29% in 2024.
- Genelux's Revenue stood at -$10.8 million in 2022, then jumped by 101.57% to $170000.0 in 2023, then sank by 95.29% to $8000.0 in 2024.
- Business Quant data shows GNLX's Revenue at $8000.0 in Q1 2024, $170000.0 in Q1 2023, and -$10.8 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.29 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 425.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 674.14 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.06 Bn |
| 10 | Genelux | 120.53 Mn | 120.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 8,000.00 |
| Mar 31, 2023 | 170,000.00 |
| Dec 31, 2022 | -10.83 Mn |
| Sep 30, 2022 | 11.00 Mn |